Galena Biopharma (SLS)
(Delayed Data from NSDQ)
$1.52 USD
-0.02 (-1.30%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $1.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Income Statements
Fiscal Year end for Galena Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 1 | 8 | 2 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 1 | 7 | 2 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 38 | 43 | 33 | 19 | 20 |
Income After Depreciation & Amortization | -38 | -42 | -25 | -17 | -20 |
Non-Operating Income | 1 | 1 | 4 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -37 | -41 | -21 | -17 | -19 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -37 | -41 | -21 | -17 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -37 | -41 | -21 | -17 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -38 | -32 | -24 | -17 | -17 |
Depreciation & Amortization (Cash Flow) | 0 | 10 | 1 | 0 | 3 |
Income After Depreciation & Amortization | -38 | -42 | -25 | -17 | -20 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 27.78 | 19.40 | 15.48 | 7.98 | 2.56 |
Diluted EPS Before Non-Recurring Items | -1.34 | -2.13 | -1.34 | -2.11 | -10.84 |
Diluted Net EPS (GAAP) | -1.34 | -2.13 | -1.34 | -2.11 | -10.92 |
Fiscal Year end for Galena Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 8.18 | 9.36 | 9.05 | 11.28 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -8.18 | -9.36 | -9.05 | -11.28 |
Non-Operating Income | NA | 0.04 | 0.09 | 0.21 | 0.18 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -8.14 | -9.27 | -8.84 | -11.10 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -8.14 | -9.27 | -8.84 | -11.10 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -8.14 | -9.27 | -8.84 | -11.10 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 32.12 | 28.36 | 28.35 | 23.55 |
Diluted EPS Before Non-Recurring Items | NA | -0.25 | -0.33 | -0.31 | -0.47 |
Diluted Net EPS (GAAP) | NA | -0.23 | -0.33 | -0.31 | -0.47 |